Skip to main content

Table 1 Baseline characteristics

From: Index of contractile asymmetry improves patient selection for CRT: a proof-of-concept study

  All subjects (n = 89) Responders (n = 66) Non-responders (n = 23) p-value
Age, yrs 68 ± 9 67 ± 10 71 ± 8 0.05
Female, n (%) 33 (37.1) 27 (40.9) 6 (26.1) 0.32
Ischemic etiology, n (%) 54 (61) 38 (57.6) 16 (69.6) 0.34
NYHA-class 1
 I, n (%) 1 (1.1) 1 (1.5) 0 (0)  
 II, n (%) 30 (33.7) 23 (34.8) 7 (30.4)  
 III, n (%) 58 (65.2) 43 (65.2) 15 (65.2)  
 ACEI/ARB, n (%) 87 (97.8) 64 (97) 23 (100) 0.99
 Beta-blockers, n (%) 85 (95.5) 63 (95.5) 22 (95.7) 0.99
 Loop diuretics, n (%) 58 (65.2) 40 (60.6) 18 (78.3) 0.2
 Aldosterone antagonists, n (%) 49 (55.1) 35 (53) 14 (60.9) 0.63
 Statins, n (%) 63 (70.8) 45 (68.2) 18 (78.3) 0.43
 eGFR < 60 ml/min/1.73 m2, n (%) 38 (42.7) 24 (36.4) 14 (60.9) 0.05
 LVESV, ml 132.4 ± 52.9 131.9 ± 56.6 133.9 ± 41.3 0.86
 LVEF, % 27.1 ± 7.1 27.3 ± 6.9 26.6 ± 7.7 0.7
 GLS, % −9.5 ± 3.4 −9.7 ± 3.7 −8.7 ± 2.5 0.12
 Mechanical dispersion, ms 97 ± 32 97 ± 32 96 ± 34 0.95
 QRS duration, ms 163 ± 20 163 ± 18 162 ± 26 0.83
  1. ACEI Angiotensin-converting enzyme inhibitors, ARB Angiotensin II receptor blockers, EF Ejection fraction, eGFR estimated glomerular filtration rate, ESV End-systolic volume, GLS Global longitudinal strain, LV left ventricle, NYHA New York Heart Association; *, p < 0.05